{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05526521",
            "orgStudyIdInfo": {
                "id": "PKM16982"
            },
            "secondaryIdInfos": [
                {
                    "id": "U1111-1266-5669",
                    "type": "REGISTRY",
                    "domain": "ICTRP"
                },
                {
                    "id": "2022-000260-22",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Sanofi",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants \u22652 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)",
            "officialTitle": "A Multi-center, Single-arm Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Male and Female Participants \u22652 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU)",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-investigate-the-pharmacokinetics-and-safety-of-dupilumab-in-participants-years-to-years-of-age-with-uncontrolled-chronic-spontaneous-urticaria-csu-liberty-csu-cupidkids"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-07-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-31",
            "studyFirstSubmitQcDate": "2022-08-31",
            "studyFirstPostDateStruct": {
                "date": "2022-09-02",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sanofi",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study is to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details include: Screening: 2 to 4 weeks; The treatment duration will be 24 weeks; Follow-up period: 12 weeks; The study duration will be 38 to 40 weeks (including screening and follow-up); The number of study visits will be 6."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Spontaneous Urticaria"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dupilumab",
                    "type": "EXPERIMENTAL",
                    "description": "Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age",
                    "interventionNames": [
                        "Drug: Dupilumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Dupilumab",
                    "description": "Injection solution Subcutaneous",
                    "armGroupLabels": [
                        "Dupilumab"
                    ],
                    "otherNames": [
                        "Dupixent"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Concentration of dupilumab in serum over time including Ctrough at Week 12 and Week 24",
                    "description": "Concentration of dupilumab in serum over time including Ctrough at Week 12 and Week 24.",
                    "timeFrame": "Week 12 and Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)",
                    "description": "Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs).",
                    "timeFrame": "Baseline to Week 36"
                },
                {
                    "measure": "Incidence of anti-drug antibodies (ADA) to dupilumab over time",
                    "description": "Incidence of anti-drug antibodies (ADA) to dupilumab over time.",
                    "timeFrame": "Baseline to Week 36"
                },
                {
                    "measure": "Change from baseline in Children's Dermatology Quality Life Index (C-DLQI) in children from 4 years to less than 12 years of age at Week 24",
                    "description": "The C-DLQI is a validated questionnaire designed to measure the impact of skin disease on children's Health-Related Quality of Life (HRQoL). The questionnaire is validated for children aged \u22654 to \\<16 years. The C-DLQI total score ranges 0 to 30. The higher the score, the greater the impact is on the child's HRQoL.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "Change from baseline in Infants' Dermatitis Quality of Life Index (IDQOL) in children from 2 years to less than 4 years of age at Week 24",
                    "description": "The IDQOL is a validated questionnaire designed for use in children aged \\<4 years. The IDLQI total score ranges 0 to 30. The higher the score, the greater the impact is on the child's HRQoL.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "Change from baseline in the modified Urticaria Activity Score (UAS7) at Week 24",
                    "description": "The UAS is a validated patient reported outcome (PRO) measure. A modified version of the UAS (mUAS) will be used in this study to account for the smaller body surface area of child and adolescent patients. Daily mUAS scores are summed over 7-day period to create the mUAS7, ranging from 0 to 42. The higher score indicates the greater urticaria activity.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "Change from baseline in the modified itch severity score over 7 days (ISS7) at Week&nbsp;24",
                    "description": "ISS ranges from 0 (absent) to 3 (intense). Daily ISS scores are summed over 7-day period to create the ISS7, ranging from 0 to 21.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "Change from baseline in the modified Hive Severity Score over 7 days (HSS7) at Week 24",
                    "description": "HSS ranges from 0 (absent) to 3 (intense, (\\>30 wheals/24 hours or large confluent areas of wheals). Daily HSS scores are summed over 7-day period to create the HSS7, ranging from 0 to 21.",
                    "timeFrame": "Baseline to Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participant must be \u2265 2 years to \\<12 years of age, at the time of signing the informed consent.\n* Participants who have history of a diagnosis of CSU prior to screening (Visit 1) or symptoms consistent with a diagnosis of CSU for at least 3 months in the Investigator's opinion.\n* Participants with CSU (characterized by recurrent itchy wheals with or without angioedema for \\>6 weeks) who remain symptomatic at the time of screening despite regular H1-antihistamine treatment.\n* Body weight within \u22655 kg to \\<60 kg.\n* Participant/parent(s)/caregiver(s)/participant's legally authorized representative, as appropriate, willing and able to comply with study visits and related procedures.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Underlying etiology for chronic urticarias other than CSU.\n* Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes.\n* Participants with a diagnosis of chronic inducible cold urticaria.\n* Participants with active AD.\n* Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the patient's participation in the study.\n* Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated.\n* Diagnosed with, suspected of, or at high risk of endoparasitic infection.\n* Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.\n* Known or suspected immunodeficiency.\n* Active malignancy or history of malignancy within 5 years before the baseline visit.\n* History of systemic hypersensitivity or anaphylaxis to dupilumab including any excipient.\n* Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "11 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Transparency email recommended (Toll free number for US & Canada)",
                    "role": "CONTACT",
                    "phone": "800-633-1610",
                    "phoneExt": "option 6",
                    "email": "Contact-US@sanofi.com"
                }
            ],
            "locations": [
                {
                    "facility": "Pediatric Dermatology of Miami Site Number : 8400015",
                    "status": "RECRUITING",
                    "city": "Coral Gables",
                    "state": "Florida",
                    "zip": "33146",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.72149,
                        "lon": -80.26838
                    }
                },
                {
                    "facility": "Treasure Valley Medical Research Site Number : 8400019",
                    "status": "RECRUITING",
                    "city": "Boise",
                    "state": "Idaho",
                    "zip": "83706",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.6135,
                        "lon": -116.20345
                    }
                },
                {
                    "facility": "Washington University School of Medicine Site Number : 8400004",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Boston Childrens Health Physicians Site Number : 8400017",
                    "status": "RECRUITING",
                    "city": "Hawthorne",
                    "state": "New York",
                    "zip": "10532",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.10732,
                        "lon": -73.79597
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center Site Number : 8400003",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Childrens Hospital Medical Center of Akron Site Number : 8400020",
                    "status": "RECRUITING",
                    "city": "Akron",
                    "state": "Ohio",
                    "zip": "44308",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.08144,
                        "lon": -81.51901
                    }
                },
                {
                    "facility": "Cincinnati Children's Hospital Medical Center - PIN Site Number : 8400001",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229-3026",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Vital Prospects Clinical Research Institute, P.C. Site Number : 8400002",
                    "status": "RECRUITING",
                    "city": "Tulsa",
                    "state": "Oklahoma",
                    "zip": "74136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.15398,
                        "lon": -95.99277
                    }
                },
                {
                    "facility": "Monroe Carell Jr. Childrens Hospital at Vanderbilt Site Number : 8400005",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240009",
                    "status": "RECRUITING",
                    "city": "Calgary",
                    "state": "Alberta",
                    "zip": "T2W 4X9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 51.05011,
                        "lon": -114.08529
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240010",
                    "status": "RECRUITING",
                    "city": "Edmonton",
                    "state": "Alberta",
                    "zip": "T5J 3S9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 53.55014,
                        "lon": -113.46871
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240007",
                    "status": "RECRUITING",
                    "city": "Hamilton",
                    "state": "Ontario",
                    "zip": "L8S1G5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.25011,
                        "lon": -79.84963
                    }
                },
                {
                    "facility": "Investigational Site Number : 1240001",
                    "status": "RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H4A 3J1",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Investigational Site Number : 3920001",
                    "status": "RECRUITING",
                    "city": "Yokohama-shi",
                    "state": "Kanagawa",
                    "zip": "232-8555",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Investigational Site Number : 3920002",
                    "status": "RECRUITING",
                    "city": "Tsu-shi",
                    "state": "Mie",
                    "zip": "514-0125",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.73333,
                        "lon": 136.51667
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014581",
                    "term": "Urticaria"
                },
                {
                    "id": "D000080223",
                    "term": "Chronic Urticaria"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017445",
                    "term": "Skin Diseases, Vascular"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17330",
                    "name": "Urticaria",
                    "asFound": "Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2129",
                    "name": "Chronic Urticaria",
                    "asFound": "Chronic Spontaneous Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19714",
                    "name": "Skin Diseases, Vascular",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}